Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Explore the 2026 PFAS-free fluoropolymer alternative landscape for coatings and membranes: regulatory drivers, material innovation trends, and patent intelligence.
Article | Rapport A 2026 landscape of mRNA therapeutic stability technology: chemical modification, LNP delivery, lyophilization, circular mRNA, and emerging IP frontiers mapped from patent and literature evidence.
Article | Rapport BGB-16673 is a CRBN-based BTK PROTAC degrader by BeiGene targeting CLL/SLL patients who relapse on BTK inhibitors. Explore the Phase II/III landscape and competitive context.
Article | Rapport Top-down vs bottom-up nanotechnology manufacturing: key differences, industrial applications, and IP landscape explained for R&D and engineering teams.
Article | Rapport EUV photomask materials are among the most strategically sensitive areas in semiconductors. Explore what the 2026 IP landscape signals for R&D and patent strategy.
Article | Rapport Explore the spintronic materials landscape in 2026: key patent trends, MRAM, spin-orbit torque, magnetic tunnel junctions, and emerging IP domains.
Article | Rapport Icotrokinra (JNJ-2113) vs. deucravacitinib: how J&J's oral IL-23 receptor antagonist challenges BMS's approved TYK2 inhibitor in the psoriasis oral therapy race.
Article | Rapport Key technical considerations for designing piezoelectric energy harvesters powering self-powered structural health monitoring nodes in civil, aerospace, and industrial systems.
Article | Rapport Explore the phase change memory materials landscape in 2026: chalcogenide alloys, GST systems, PCM cell engineering, and how PatSnap Eureka accelerates IP research.
Article | Rapport ISO 26262 addresses hardware and software faults in automotive systems; ISO 21448 SOTIF targets insufficiencies in design and perception for autonomous driving.
Article | Rapport How machine learning, generative models, and self-driving labs are replacing trial-and-error alloy development—mapped across aerospace, EV, and energy sectors.
Article | Rapport Explore the core engineering challenges of developing reliable high-temperature sensors for continuous emissions monitoring (CEMS) in industrial stacks — from material degradation to signal drift.
Article | Rapport Explore the 2026 anti-reflective coating materials landscape for solar glass: key chemistries, deposition methods, IP activity, and innovation trends shaping the sector.
Article | Rapport TAR-200 (Inlexzo) is Janssen's osmotic intravesical gemcitabine device targeting MIBC and high-risk NMIBC. Explore the patent landscape and Phase III pivotal data.
Article | Rapport Inclisiran's ORION-4 Phase III outcomes trial, siRNA vs PCSK9 antibody LDL-C reductions, MACE data, and the evolving cardiovascular IP landscape.